LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
4.770
-0.020 (-0.42%)
At close: Aug 18, 2026, 4:00 PM EDT
4.850
+0.080 (1.68%)
After-hours: Aug 18, 2026, 7:36 PM EDT
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $5.49M in the quarter ending June 30, 2026, with 9.72% growth. This brings the company's revenue in the last twelve months to $21.48M, up 329.50% year-over-year. In the year 2025, LENZ Therapeutics had annual revenue of $19.09M.
Revenue (ttm)
$21.48M
Revenue Growth
+329.50%
P/S Ratio
7.02
Revenue / Employee
$141,283
Employees
152
Market Cap
149.88M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.09M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cue Biopharma | 37.66M |
| Equillium | 4.39M |
| Milestone Pharmaceuticals | 2.34M |
| Kazia Therapeutics | 1.27M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
| Outlook Therapeutics | -1.16M |
LENZ News
- 1 day ago - Lenz Therapeutics reports Q2 EPS ($1.02), consensus ($1.07) - TheFly
- 1 day ago - Lenz Therapeutics price target lowered to $10 from $20 at Citi - TheFly
- 1 day ago - Lenz Therapeutics price target lowered to $7 from $12 at Piper Sandler - TheFly
- 1 day ago - Lenz Therapeutics downgraded to Neutral from Buy at BofA - TheFly
- 7 days ago - LENZ Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 7 days ago - LENZ Therapeutics Earnings release: Q2 2026 - Filings
- 7 days ago - LENZ Therapeutics Quarterly report: Q2 2026 - Filings
- 7 days ago - LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire